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Abstract
Objective: Receptor activator of nuclear factor-kappa B ligand (RANKL) appears to be
an osteoclast-activating factor, bearing an important role in the pathogenesis of multiple
myeloma. Some studies demonstrated that U-266 myeloma cell line and primary myeloma
cells expressed RANK and RANKL. It had been reported that the expression of myeloid
and monocytoid markers was increased by co-culturing myeloma cells with hematopoietic
stem cells (HSCs). This study also attempted to show the molecular mechanism of RANK
and RANKL on differentiation capability of human cord blood HSC to osteoclast, as well
as expression of calcitonin receptor (CTR) on cord blood HSC surface.
Materials and Methods: In this experimental study, CD133+ hematopoietic stem cells were
isolated from umbilical cord blood and cultured in  the presence of  macrophage colony-stim-
ulating factor (M-CSF) and RANKL. Osteoclast differentiation was characterized by using
tartrate-resistant acid phosphatase (TRAP) staining, giemsa staining, immunophenotyping,
Results: Hematopoietic stem cells expressed RANK before and after differentiation into
expression of RANK after differentiation. Expression of CTR mRNA showed TRAP reac-
tion was positive in some differentiated cells, including osteoclast cells.
Conclusion: Presence of RANKL and M-CSF in bone marrow could induce HSCs
differentiation into osteoclast.
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Introduction
Remodelling procedure of bone is composed
of resorption and formation of this organ (1).
Mesenchymal stem cells are responsible for os-
teoblast production during bone formation and
osteoclasts are considered as bone-resorbing
multinuclear cells originated from hematopoi-
etic stem cells (HSCs) (2, 3). Physiologic condi-
tion establishes balance between osteoblast and
osteoclast activities. Misbalance in the produc-
tion or activity of osteoclasts causes bone dis-
eases such as multiple myeloma (MM) (1). MM
is a hematologic disease (4-7), which is deter-
mined by the monoclonal expansion of malig-
nant plasma cells in the bone marrow (BM) (8).
Bone damages including bone lesion, spinal
cord compaction and also bone fracture are hall-
marks of myeloma bone disease (MBD), as po-
